Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults is a paper indexed in PICO Portal from OpenAlex.
How many citations does Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults have?
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults has 75 citations in the OpenAlex counts PICO Portal stores.
When was Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults published?
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults has 2020 year in the PICO Portal index.
What is the open-access status of Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults?
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults has gold oa status in the PICO Portal index.
What is the DOI of Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults?
The DOI for Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults is on the source record.
What is the PMID of Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults?
The PMID for Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults is on the source record.
What is the OpenAlex record for Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults?
The OpenAlex for Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults is on the source record.